IN2015DN03936A - - Google Patents
Info
- Publication number
- IN2015DN03936A IN2015DN03936A IN3936DEN2015A IN2015DN03936A IN 2015DN03936 A IN2015DN03936 A IN 2015DN03936A IN 3936DEN2015 A IN3936DEN2015 A IN 3936DEN2015A IN 2015DN03936 A IN2015DN03936 A IN 2015DN03936A
- Authority
- IN
- India
- Prior art keywords
- plgas
- pharmaceutically
- acceptable salt
- active ingredient
- sustained release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Abstract
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0526247A GB0526247D0 (en) | 2005-12-22 | 2005-12-22 | Organic compounds |
EP06119086 | 2006-08-17 | ||
PCT/EP2006/012313 WO2007071395A1 (en) | 2005-12-22 | 2006-12-20 | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN03936A true IN2015DN03936A (en) | 2015-10-02 |
Family
ID=37772904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3936DEN2015 IN2015DN03936A (en) | 2005-12-22 | 2006-12-20 |
Country Status (22)
Country | Link |
---|---|
US (6) | US20090004283A1 (en) |
EP (3) | EP2359809B1 (en) |
JP (4) | JP2009520727A (en) |
KR (5) | KR101458728B1 (en) |
CN (1) | CN103251929A (en) |
AR (1) | AR058591A1 (en) |
AU (1) | AU2006328950B2 (en) |
BR (2) | BRPI0620063B8 (en) |
CA (1) | CA2631811C (en) |
CL (1) | CL2018003398A1 (en) |
EC (1) | ECSP088560A (en) |
ES (2) | ES2755032T3 (en) |
IL (1) | IL191842A0 (en) |
IN (1) | IN2015DN03936A (en) |
MA (1) | MA30064B1 (en) |
NO (1) | NO20082988L (en) |
PE (1) | PE20071139A1 (en) |
PL (2) | PL1968549T3 (en) |
PT (2) | PT1968549E (en) |
RU (1) | RU2464972C2 (en) |
TW (2) | TWI468172B (en) |
WO (1) | WO2007071395A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2500014T3 (en) | 2007-06-06 | 2018-12-03 | Debiopharm Res & Manufacturing Sa | Slow release pharmaceutical composition made from microparticles |
US8470360B2 (en) * | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
ES2324009B1 (en) * | 2007-11-23 | 2010-05-21 | Gp Pharm S.A. | PHARMACEUTICAL COMPOSITION OF SUSTAINED RELEASE OF SOMATOSTATINE OR AN ANALOG OF HIS. |
AU2013201877B2 (en) * | 2008-01-30 | 2015-01-29 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
EP2247282B1 (en) * | 2008-01-30 | 2014-08-20 | Novartis AG | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
MX2011002836A (en) | 2008-09-17 | 2011-04-28 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery. |
AR074603A1 (en) * | 2008-12-15 | 2011-01-26 | Novartis Ag | FORMULATION OF OCTREOTIDE DEPOSIT WITH EXPOSURE LEVELS CONSTANTLY HIGH. METHOD. KIT |
JP2012515791A (en) * | 2009-01-23 | 2012-07-12 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | Controlled release system derived from polymer hybrids |
US20120022137A1 (en) * | 2010-07-21 | 2012-01-26 | Rivers Hongwen M | METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
US20120156304A1 (en) * | 2010-12-15 | 2012-06-21 | Thomas Tice | Branched polyol polyesters, blends, and pharmaceutical formulations comprising same |
PL3199146T3 (en) | 2011-04-25 | 2020-03-31 | Shan Dong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
CN102488619B (en) * | 2011-12-05 | 2014-08-06 | 上海交通大学 | Device for continuously producing exenatide microspheres and method for controlling release rate of microspheres |
WO2016126830A1 (en) | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
JP6165356B2 (en) * | 2015-06-26 | 2017-07-19 | オリンパス株式会社 | Endoscope system |
KR102142026B1 (en) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | Method of preparing sustained release drug microparticles with ease of release control |
CN111214643A (en) * | 2020-03-11 | 2020-06-02 | 苏州善湾生物医药科技有限公司 | Octreotide composition based on subcutaneous gel sustained release, preparation method and application |
JP6792900B1 (en) * | 2020-05-08 | 2020-12-02 | エム・テクニック株式会社 | Microspheres in which bioactive substances are uniformly dispersed and sustained-release preparations containing them |
CN116327735A (en) * | 2020-05-08 | 2023-06-27 | M技术株式会社 | Microsphere with uniformly dispersed main agent and sustained release preparation containing same |
JP6810502B1 (en) * | 2020-05-08 | 2021-01-06 | エム・テクニック株式会社 | Microspheres in which bioactive substances are uniformly dispersed and sustained-release preparations containing them |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE3062075D1 (en) * | 1979-11-27 | 1983-03-24 | Sandoz Ag | Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
CH683149A5 (en) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Process for the preparation of microspheres of a biodegradable polymeric material. |
WO1993015722A1 (en) * | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
KR100260632B1 (en) * | 1992-12-28 | 2000-07-01 | 성재갑 | Implantable somatotropin composition |
US5603960A (en) * | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
US6447796B1 (en) * | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
US6197350B1 (en) * | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
IL133105A (en) * | 1997-06-04 | 2004-09-27 | Debio Rech Pharma Sa | Implants for controlled release of pharmaceutically active principles and method for making same |
ES2169980B1 (en) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS. |
KR100392501B1 (en) * | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | Preparation Method for Sustained Release Microparticles by Multiple Emulsion Method and Micropartic les Thereof |
ATE374598T1 (en) * | 2002-03-15 | 2007-10-15 | Alrise Biosystems Gmbh | MICROPARTICLES AND METHOD FOR THE PRODUCTION THEREOF |
EP1581181B1 (en) * | 2002-11-06 | 2008-12-24 | ALZA Corporation | Controlled release depot formulations |
US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
KR100466637B1 (en) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | Method for preparing a mixed formulation of sustained release microspheres by continuous one-step process |
CA2533314C (en) * | 2003-07-18 | 2013-07-09 | Oakwood Laboratories, L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
CA2533592C (en) * | 2003-07-23 | 2015-11-10 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
SI1786400T1 (en) * | 2004-08-12 | 2009-08-31 | Quest Pharmaceutical Services | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
-
2006
- 2006-12-20 CA CA2631811A patent/CA2631811C/en active Active
- 2006-12-20 BR BRPI0620063A patent/BRPI0620063B8/en active IP Right Grant
- 2006-12-20 PT PT68410596T patent/PT1968549E/en unknown
- 2006-12-20 IN IN3936DEN2015 patent/IN2015DN03936A/en unknown
- 2006-12-20 KR KR1020137004517A patent/KR101458728B1/en active IP Right Grant
- 2006-12-20 PT PT101753820T patent/PT2359809T/en unknown
- 2006-12-20 PE PE2006001665A patent/PE20071139A1/en not_active Application Discontinuation
- 2006-12-20 JP JP2008546248A patent/JP2009520727A/en active Pending
- 2006-12-20 ES ES10175382T patent/ES2755032T3/en active Active
- 2006-12-20 WO PCT/EP2006/012313 patent/WO2007071395A1/en active Application Filing
- 2006-12-20 ES ES06841059.6T patent/ES2492641T3/en active Active
- 2006-12-20 AR ARP060105668A patent/AR058591A1/en unknown
- 2006-12-20 EP EP10175382.0A patent/EP2359809B1/en active Active
- 2006-12-20 EP EP06841059.6A patent/EP1968549B1/en active Active
- 2006-12-20 EP EP19188892.4A patent/EP3603623A1/en not_active Withdrawn
- 2006-12-20 KR KR1020137004518A patent/KR20130024987A/en active Application Filing
- 2006-12-20 KR KR1020087014985A patent/KR101245919B1/en active IP Right Review Request
- 2006-12-20 KR KR1020137004520A patent/KR20130024988A/en not_active Application Discontinuation
- 2006-12-20 KR KR1020147031146A patent/KR20140133968A/en not_active Application Discontinuation
- 2006-12-20 AU AU2006328950A patent/AU2006328950B2/en active Active
- 2006-12-20 PL PL06841059T patent/PL1968549T3/en unknown
- 2006-12-20 US US12/158,345 patent/US20090004283A1/en not_active Abandoned
- 2006-12-20 PL PL10175382T patent/PL2359809T3/en unknown
- 2006-12-20 CN CN2013101523825A patent/CN103251929A/en active Pending
- 2006-12-20 RU RU2008129626/15A patent/RU2464972C2/en active
- 2006-12-20 BR BR122019027412A patent/BR122019027412B8/en active IP Right Grant
- 2006-12-21 TW TW103107772A patent/TWI468172B/en active
- 2006-12-21 TW TW95148218A patent/TWI469788B/en active
-
2008
- 2008-05-29 IL IL191842A patent/IL191842A0/en unknown
- 2008-06-18 MA MA31048A patent/MA30064B1/en unknown
- 2008-06-19 EC EC2008008560A patent/ECSP088560A/en unknown
- 2008-07-02 NO NO20082988A patent/NO20082988L/en not_active Application Discontinuation
-
2013
- 2013-04-25 JP JP2013092845A patent/JP6239851B2/en active Active
-
2014
- 2014-10-08 JP JP2014207464A patent/JP6178772B2/en active Active
- 2014-10-16 US US14/516,016 patent/US20150037420A1/en not_active Abandoned
-
2015
- 2015-12-22 US US14/977,801 patent/US20160120935A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115579A patent/JP2016216467A/en not_active Withdrawn
-
2018
- 2018-01-17 US US15/873,473 patent/US20180140662A1/en not_active Abandoned
- 2018-11-29 CL CL2018003398A patent/CL2018003398A1/en unknown
-
2020
- 2020-03-10 US US16/813,864 patent/US20200206306A1/en not_active Abandoned
-
2022
- 2022-06-07 US US17/834,014 patent/US20220296675A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN03936A (en) | ||
TN2011000261A1 (en) | Octreotide depot formulation with constantly high exposure levels | |
HK1200092A1 (en) | Sustained release formulations | |
TW200716119A (en) | A solid pharmaceutical dosage formulation | |
MX2007005156A (en) | Improved carrier formulation. | |
MX2010004576A (en) | Novel pyrimidine derivatives. | |
IL214617A0 (en) | Use of controlled release formulations of octreotide | |
IL184460A0 (en) | Sustained release pharmaeutical formulations | |
IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
MX2009004439A (en) | Ibuprofen composition. | |
DE602006002260D1 (en) | INSECT-REPRODUCTIVE COMPOSITIONS WITH DELAYED RELEASE | |
MX2007003196A (en) | Agent and food for preventing/improving functional digestive disorder. | |
TW200942524A (en) | Novel aminomethyl benzene derivatives | |
TW200621160A (en) | Anti-termite agent | |
IL189885A0 (en) | Storage-stable sulphonamide formulations | |
MX2010008365A (en) | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers. | |
MX2007013327A (en) | Extended release formulations. | |
MX2007011826A (en) | Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same. | |
PL376130A1 (en) | Controlled releases system containing temozolomide | |
BRPI0417265A (en) | pharmaceutical composition comprising an active ingredient and sulfobetaine | |
WO2007137216A3 (en) | Gastroretentive sustained release formulations | |
TNSN08271A1 (en) | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers | |
GB0401634D0 (en) | A surfactant | |
GB0327390D0 (en) | Pharmaceutical formulations | |
EP1682125A4 (en) | Multiple active agents such as anthelmintics sustained release delivery |